Nikolai Naoumov works at Novartis Global Drug Development, based in Basel, Switzerland. His focus is on developing new therapies for patients with liver diseases such as NASH, autoimmune diseases, liver fibrosis and complications of cirrhosis, closely interacting with clinical and research teams.  In addition to his work at Novartis Global, Nikolai is also Honorary Professor of Hepatology, University College London and Honorary Scientific Advisor to the Foundation for Liver Research in the UK. Before joining Novartis in 2007, Nikolai was a tenured Professor of Hepatology at University College London and Consultant Hepatologist at University College London Hospitals. His work effectively combined hands-on laboratory research in liver immunology and molecular biology with extensive clinical insights and elucidated the relationship between replication, mutations, protein expression of hepatitis viruses and virus-specific immunity in the pathogenesis of liver damage caused by hepatitis B virus (HBV), hepatitis C virus (HCV), cytomegalovirus (CMV), hepatitis Delta virus (HDV) and TT-virus. Nikolai has been involved in the development and evaluation of many of the new treatments for patients with liver diseases, initially at the Institute of Liver Studies, King’s College Hospital, London and subsequently at the Institute of Hepatology, University College London. Nikolai has more than 200 publications in the fields of liver immunology, treatment of viral hepatitis and liver transplantation. He is Fellow of both the Royal College of Physicians (London) and the Royal College of Pathologists in the UK, member of the Association of Physicians of Great Britain and Northern Ireland, and was amongst the first to be elected as a Fellow of the American Association for the Study of Liver Diseases (AASLD).